AlphAIAlphAI — Financial news for AI agents
investing.comSEP 242 min read$INSM

Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target

Goldman Sachs initiated coverage on Insmed Inc. (NASDAQ:INSM) with a buy rating and a $188 price target, citing strong revenue growth and high gross margins. The company's revenue grew 186% to $1.14 billion over the last twelve months, with analysts projecting continued sales growth. Management expects peak sales of over $14 billion across its lead assets. The FDA granted priority review for Arikayce's expanded use, and the company received regulatory approval for Brinsupri in Japan.

Original reporting
investing.com
Published Sep 24, 2026, 10:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 12:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$INSM
Bullish
medium confidence
Mentioned
$INSM
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$INSMBullishMed
01

Why it matters

The initiation could attract new institutional interest and support the stock price in the near term.

02

Market read

Analyst coverage is a primary catalyst that may influence trading decisions for INSM.

03

What to watch

Potential reimbursement challenges and the need for broader market adoption of Brinsupri.

Relevance 6/10Novelty 6/10Timing: today

Background

Goldman Sachs' research note adds a new buy rating and a higher price target for Insmed, a company with recent revenue growth and pipeline progress.

Company-level read

Ticker impact

$INSMBullishMedium confidence
Context

Goldman Sachs initiated coverage on Insmed with a buy rating and a $188 price target, up from the current $118.34 price.

Expected impact

Potential upside of 10-15% if market reacts to the new target.

Evidence & confidence

Coverage initiation is a fresh catalyst; however, the target is within a range of other analysts, limiting magnitude.

Market effects

Sector

Highlights continued optimism in the biotech respiratory‑therapy niche.

Regional

U.S. biotech sector may see modest uplift.

Global

Limited to investors focused on specialty pharma.

Counterpoint

What could challenge this read

The target may be overly optimistic given competitive pressures and pending regulatory reviews.

Key entities

  • Analyst
    Goldman Sachs

    Initiated coverage with a buy rating.

  • Company
    Insmed Inc.

    Biopharmaceutical firm developing respiratory therapies.

Read at source← All news

Related articles

SEP 28
$INSMMedAI 8/10

Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?

Insmed (INSM) announced the FDA granted priority review for its ARIKAYCE lung drug, setting a January 2027 decision date. The application seeks full approval for broader use in treating MAC lung disease. Clinical trial results showed significant improvements in respiratory symptoms and bacterial conversion rates. Success could expand the patient pool and increase revenue, but regulatory, tolerability, and commercialization risks remain.

insidermonkey.com2 min
SEP 22
$INSMHighAI 8/10

FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce

Insmed (INSM) announced the FDA accepted its filing for Arikayce's label expansion to treat newly diagnosed MAC lung disease, with a decision expected by Jan. 28, 2027. The filing is supported by positive phase IIIb ENCORE study results. Arikayce sales grew 7% YoY to $214.4M in H1 2026, with full-year sales projected at $450M-$470M. The expansion could significantly increase Arikayce's market potential, according to the company.

zacks.com2 min
SEP 21
HighAI 8/10

Why is Insmed stock climbing today?

Insmed stock rose 2.0% in pre-market trading after the FDA accepted and granted Priority Review to its sNDA for ARIKAYCE, targeting a decision by January 28, 2027. The application seeks full approval for the drug, backed by Phase 3b ENCORE study results. Full approval would expand ARIKAYCE's use to newly diagnosed patients and those with recurrent infections. Insmed also plans to engage Japan's pharmaceutical regulator in Q4 2026 for potential label expansion.

investing.com2 min
SEP 21
$INSMHighAI 8/10

Insmed stock rises on FDA priority review for Arikayce

Insmed Inc. (NASDAQ:INSM) shares rose 2% premarket after the FDA granted priority review to its sNDA for Arikayce, targeting MAC lung disease. The FDA set a review deadline of January 28, 2027. Arikayce, approved in 2018, could see expanded use if the application succeeds. The sNDA is backed by Phase 3b ENCORE study results showing significant improvements in respiratory symptoms and culture conversion.

investing.com1 min